gp iib-iiia

Roxifiban acetate(DMP 754 acetate) is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Gantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist.

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb/IIIa (GP IIb-IIIa).

Tirofiban (L700462) (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

Fradafiban binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb/IIIa antagonist.

ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. It inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. ZD 2486 is applicable in research concerning diseases linked to undesirable platelet aggregation, such as acute coronary syndromes, unstable angina, acute myocardial infarction, and complications from cardiovascular interventions.

UR-12947 is a glycoprotein (GP) IIb-IIIa antagonist that effectively inhibits platelet aggregation in human platelet-rich plasma, with an IC50 value of 3.5 nM. It is utilized for the study of arterial thrombotic diseases.

MK 0852 is the platelet GP IIb/IIIa cyclic heptapeptide antagonist.

SK&F 107260 is an RGD-containing peptide. It is a potent GP IIb/IIIa antagonist and a vitronectin antagonist.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Fradafiban (BIBU-52) hydrochloride is a nonpeptide antagonist of the platelet glycoprotein IIb/IIIa complex, exhibiting a dissociation constant (Kd) of 148 nM for binding affinity to the human platelet GP IIb/IIIa.